The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
10/26/2009
. If
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
opportunity click
send
me change notification emails
.
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
printed document.
Document Type:
Grants Notice
Funding Opportunity Number:
RFA-CA-10-003
Opportunity Category:
Discretionary
Posted Date:
Oct 26, 2009
Creation Date:
Oct 26, 2009
Original Closing Date for Applications:
Sep 30, 2010
Current Closing Date for Applications:
Sep 30, 2010
Archive Date:
Oct 31, 2010
Funding Instrument Type:
Grant
Category of Funding Activity:
Education
Health
Category Explanation:
Expected Number of Awards:
Estimated Total Program Funding:
$2,250,000
Award Ceiling:
$200,000
Award Floor:
CFDA Number(s):
93.393
--
Cancer Cause and Prevention Research
93.394
--
Cancer Detection and Diagnosis Research
93.395
--
Cancer Treatment Research
93.396
--
Cancer Biology Research
Cost Sharing or Matching Requirement:
No
Eligible Applicants
State governments
Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility:
Other Eligible Applicants include the following:
Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); U.S. Territory or Possession.
Agency Name
National Institutes of Health
Description
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications that propose exploratory research projects on the initial application of emerging analytical technologies as laboratory or clinical tools. An emerging technology is defined as one that has passed the initial developmental stage, but has not yet been evaluated within the context of its intended use. Projects proposed in response to this FOA should have the potential to produce a major impact in a broad area of cancer-relevant research. If successful, these technologies would accelerate research in cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA solicits R21 applications that have high potential impact and allows for an element of technical risk; preliminary data are not required. All projects must include quantitative milestones (i.e. technical metrics that determine whether the specific aims have been accomplished). Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this solicitation and will be returned as non-responsive. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Mechanism of Support. This FOA will utilize the R21 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-CA-10-004, that solicits applications under the NIH Application R33 grant mechanism.
Funds Available and Anticipated Number of Awards. The NCI intends to commit a total of approximately $2,250,000 to this FOA in fiscal year 2010 to fund up to 7 applications in response to this FOA.
Budget and Project Period. The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year.
